CAII-IN-13 

CAII-IN-13 is a human carbonic anhydrase inhibitor, with a K_i of 65.9 nM against human carbonic anhydrase II and a K_i of 968.4 nM against human carbonic anhydrase I. CAII-IN-13 functionally inhibits the catalytic activities of human carbonic anhydrase II and human carbonic anhydrase I. CAII-IN-13 satisfies the Lipinski's rule of five and may possess physicochemical properties and pharmacokinetic profiles associated with in vivo bioavailability^[1].

CAII-IN-13 (compound 3D) exhibits favorable predicted pharmacokinetic properties, including high gastrointestinal absorption, a bioavailability score of 0.55, no blood-brain barrier permeability, and only one deviation from the Lipinski's five rules^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

464.97

C₂₄H₂₁ClN₄O₂S

O=S(C1=CC=C(CC/N=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC=C(Cl)C=C4)C=C1)(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Panchal V, et al. Novel pyrazole-based Schiff base with carbonic anhydrase inhibitory activity: synthesis, characterization, enzyme inhibition and in silico studies[J]. Chemical Papers, 2026: 1-14.